11β-methyl-19-nortestosterone | 18046-77-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11β-methyl-19-nortestosterone
• 英文别名: 11beta-Methyl-19-nortestosterone；(8R,9S,10R,11S,13S,14S,17S)-17-hydroxy-11,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 18046-77-0
• 化学式: C₁₉H₂₈O₂
• 分子量: 288.43
• InChiKey: QCNNHARIRLYUAB-CTPXPINYSA-N

物化性质

• 熔点：
  158-160 °C
• 沸点：
  439.4±45.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  11β-methyl-19-nortestosterone 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 copper(I) bromide dimethylsulfide complex 、 二甲基硫 、 对甲苯磺酸 作用下， 以 甲醇 、 乙醚 、 水 、 苯 为溶剂， 反应 6.75h， 生成 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one
  参考文献：
  名称：

  7α,11β-Dimethyl-19-nortestosterone: a potent and selective androgen response modulator with prostate-sparing properties

  摘要：

  7alpha, 11beta-Dimethyl-19-nortestosterone, made by 1,6-methyl addition to 17beta-acetoxy- 11beta-methylestra-4,6-dien-3-one, was a highly potent and selective androgen response modulator, with enhanced androgen receptor binding, androgenic activity and anabolic: androgenic ratio over its two monomethyl homologs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.076
• 作为产物：
  描述：

  11β-methyl-17β-hydroxyestr-5(10)-en-3-one 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以35%的产率得到11β-methyl-19-nortestosterone
  参考文献：
  名称：

  WO2006/83618

  摘要：

  公开号：

文献信息

• Nandrolone 17 Beta-Carbonates
  申请人：Blye Richard P.

  公开号：US20080167283A1

  公开（公告）日：2008-07-10

  Disclosed are compounds of the formula (I) wherein R is C 1 -C 30 alkyl, which may be optionally further substituted with one or more C 5 -C 8 cycloalkyl groups, or a C 5 -C 12 cycloalkyl, which may be optionally substituted with one or more C 1 -C 30 alkyl groups, R′ is hydrogen or lower alkyl, R″ is a C 1 -C 30 alkyl or halo, and the bond between C14 and C15 can be a single bond or double bond. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use thereof. These compounds can find use in treating a number of diseases or conditions such as hypogonadism, hypergonadism, osteoporosis, and anemia, in providing hormonal therapy and contraception, as an anabolic agent, and in suppressing the release of hormones such as the luteinizing hormone.

  本发明涉及式（I）的化合物，其中R是C1-C30烷基，可以选择性地进一步取代一个或多个C5-C8环烷基基团或C5-C12环烷基，可以选择性地取代一个或多个C1-C30烷基基团，R′是氢或较低的烷基，R″是C1-C30烷基或卤素，并且C14和C15之间的键可以是单键或双键。本发明还涉及包含这样的化合物的制药组合物以及使用它们的方法。这些化合物可以用于治疗多种疾病或症状，例如性腺功能减退症，性腺功能亢进症，骨质疏松症和贫血，提供激素疗法和避孕，作为一种合成代谢物和抑制黄体生成素释放的荷尔蒙。
• Strategy in drug reseabch. Synthesis and study of the psogestational and ovulation inhibitory activity of a series of 11β-substituted-17α-ethynyl-4-estren-17β-ols
  作者：A.J.v.d. Broek、A.I.A. Broess、M.J.v.d. Heuvel、H.P. de Jongh、J. Leemhuis、K.H. Schonemann、J. Smits、J. de Visser、N.P. van Vliet、F.J. Zeelen

  DOI：10.1016/0039-128x(77)90095-2

  日期：1977.10

  Using the strategy based on the Hansch method which analyses effects of substituents on biological activity in terms of their hydrophobic, electronic and steric effects we selectively synthesised a series of 11beta-substituted-17alpha-ethynyl-4-estren-17beta-ols that combine ease of synthesis with good discrimination between these factors aiming at finding the compounds with optimum biological activity in that series. The compounds were tested quantitatively in the Clauberg test (rabbit) and the ovulation inhibition test (rat). The differences in biological activity could reasonably be correlated with two steric effects introduced by the 11beta-substituent. These were a change in the overall shape of the 11beta-substituent and the angular methyl group, and direct steric hindrance of the steroid-receptor protein binding. Some exceptions were found possibly due to metabolic conversion of these compounds to the corresponding 11beta-substituted-17alpha-ethynyl-1,3,5(10)-estra-triene-3,17beta-diols.
• NANDROLONE 17ß-CARBONATES
  申请人：Government of the United States of America, Represented by the Secretary, Department of Health and Human Services

  公开号：EP1846434B1

  公开（公告）日：2009-03-25
• COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS
  申请人：INITIUM INNOVATIONS, INC.

  公开号：US20190298646A1

  公开（公告）日：2019-10-03

  Disclosed herein are sustained release compositions of anti-inflammatory agents and methods of use. In some embodiments, the biodegradable sustained release compositions comprise an effective amount of an anti-inflammatory agent selected from a steroid, ta calcineurin inhibitor, a PDE4 inhibitor, an antibiotic, and combinations thereof. Also disclosed herein are methods to treat an inflammatory condition in a subject by administering a biodegradable sustained release compositions of the anti-inflammatory agent.
• MODULATION OF SEX STEROID HORMONE PRODUCTION AND ACTIVITY FOR TREATING AND PREVENTING HERNIAS
  申请人：Northwestern University

  公开号：US20210283144A1

  公开（公告）日：2021-09-16

  Disclosed are methods and compositions for treating and/or preventing hernias in subjects in need thereof. The disclosed methods of treatment and/or preventing may include methods for treating and/or preventing hernias in subject in need thereof by administering to the subject a therapeutic agent that modulates sex steroid hormone production and/or activity in the subject. Hernias treated and/or prevented by the disclosed methods may include, but are not limited to, inguinal hernias, femoral hernias, umbilical hernias, hiatal hernias, incisional hernias, and diastasis recti.